Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Entresto vs. usual BP therapy in LVAD patients
NCT03279861Phase 4Withdrawn
- Sponsor
- University of Maryland, Baltimore
- Start
- Nov 2017
- Primary completion
- Nov 2018
- Modality
- Small Molecules
01
Overview
Phase 4, randomised, open-label trial of sacubitril + valsartan in hypertension (HTN) (2 arms), sponsored by University of Maryland, Baltimore. Primary endpoint: Time spent with MAP < 85 mmHg at 2 months. Planned start Nov 2017; status: withdrawn.
02
Drugs
sacubitril + valsartan
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on NCT03279861.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03279861.